3-aminophenol | CAS:591-27-5

We serve 3-aminophenol CAS:591-27-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-aminophenol

Chemical Name:3-aminophenol
CAS.NO:591-27-5
Synonyms:3-amino-phenol; Fouramine EG; m-Hydroxyaniline;
Molecular Formula:C6H7NO
Molecular Weight:109.12600
 
Physical and Chemical Properties:
Density:0.99;
Melting point:121oC;
Boiling point:164oC;
Flash point:155oC;
 
Specification:
Appearance:Off-white crystalline powder
Purity(HPLC):≥99.0%
Ash:≤0.1%
Loss on drying:≤0.5%
Fe content:≤50ppm
Heavy metal:≤10ppm
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Hair dyes intermediate
 



Contact us for information like 3-aminophenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,m-Hydroxyaniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-amino-phenol Use and application,Fouramine EG technical grade,usp/ep/jp grade.


Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.2-Chloro-4-dibenzofuran-4-yl-6-phenyl-[1,3,5]triazine manufacturer We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.3,4-Dihydroxybenzaldehyde supplier We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol vendor It also said it would bar South Koreans from visiting China as tourists.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.